Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

upload.jpg

Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance

At the World AMR Congress, Recce Pharmaceuticals showcased a synthetic broad-spectrum antibiotic designed to combat antimicrobial resistance (AMR) by effectively targeting bacterial mutations. Graham from the company emphasized the compound's ability to treat various infections, like urinary tract infections, without distinguishing between 'good' and 'bad' bacteria, enabling quick and reliable patient care. He criticized the industry's repetitive strategies and advocated for innovation, highlighting their unique approach using polymeric chemistry to maintain effectiveness across different pH levels. While acknowledging the challenges of introducing novel treatments to the market, Graham outlined the essential development stages, including patenting, regulatory navigation, and achieving clinical outcomes, all of which are crucial for attracting investor interest and enhancing AMR treatment.